5 mins | 30 mins | Hourly | Daily | Weekly |
---|---|---|---|---|
BUY | BUY | BUY | BUY | BUY |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MA5 | 29.85▲ | 29.63▲ | 29.63▲ | 29.39▲ | 29.55▲ |
MA10 | 29.48▲ | 29.20▲ | 29.20▲ | 29.19▲ | 29.68▲ |
MA20 | 29.07▲ | 28.89▲ | 28.87▲ | 29.45▲ | 29.04▲ |
MA50 | 28.99▲ | 29.11▲ | 29.29▲ | 29.66▲ | 30.19▼ |
MA100 | 29.48▲ | 29.59▲ | 29.53▲ | 29.11▲ | 29.49▲ |
MA200 | 29.37▲ | 29.12▲ | 28.97▲ | 29.83▲ | 27.65▲ |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MACD | 0.154▲ | 0.168▲ | 0.179▲ | 0.063▲ | 0.113▲ |
RSI | 83.896▲ | 80.831▲ | 75.808▲ | 57.662▲ | 53.208▲ |
STOCH | 99.925▲ | 99.942▲ | 99.942▲ | 63.913 | 59.421 |
WILL %R | -0.347▲ | -0.347▲ | -0.347▲ | -3.365▲ | -21.270▲ |
CCI | 103.692▲ | 152.978▲ | 152.959▲ | 126.545▲ | 31.346 |
Friday, August 15, 2025 07:55 AM
The company’s shares of common stock were previously quoted on the OTC Markets, Pink Tier and ceased to be quoted at the close of business on ...
|
Friday, August 15, 2025 02:23 AM
Propanc Biopharma, Inc. (OTC Pink: PPCB) ("Propanc" or the "Company"), a biopharmaceutical company developing novel cancer treatments for patients ...
|
Thursday, August 14, 2025 08:14 PM
Propanc common stock expected to begin trading on Nasdaq under the symbol PPCBMELBOURNE, Australia, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (OTC Pink: PPCB) (“Propanc” or the ...
|
date | open | high | low | close | volume |
---|---|---|---|---|---|
15/08/25 | 29.86 | 30.0999 | 29.73 | 30.04 | 48,337 |
14/08/25 | 29.42 | 29.65 | 29.40 | 29.615 | 48,100 |
13/08/25 | 29.27 | 29.60 | 29.27 | 29.60 | 28,073 |
12/08/25 | 28.65 | 29.085 | 28.65 | 29.084 | 24,700 |
11/08/25 | 28.60 | 28.72 | 28.5999 | 28.63 | 24,478 |
08/08/25 | 28.68 | 28.77 | 28.5215 | 28.65 | 20,345 |
07/08/25 | 28.80 | 28.80 | 28.32 | 28.44 | 108,305 |
06/08/25 | 29.28 | 29.28 | 28.86 | 28.93 | 102,300 |
05/08/25 | 29.38 | 29.38 | 29.155 | 29.2711 | 31,893 |
04/08/25 | 29.33 | 29.62 | 29.185 | 29.62 | 23,049 |
|
|
||||
|
|
||||
|
|